JD BioWorks Research Resources
Research Library
Source-conscious guides to analytical methods, documentation, compound literature, regulatory developments, and evidence interpretation.
Browse articles by month, topic, or compound
Filtered Research
14 articles
Cagrilintide and Semaglutide: Why Researchers Combined Amylin and GLP-1
CagriSema combines the amylin analogue cagrilintide with the GLP-1 agonist semaglutide. Here is why researchers paired them, what human trials found, and what the evidence does not establish.
Read article
Can Semaglutide Cause Blindness? What the NAION Evidence Actually Shows
Semaglutide has been linked to a rare optic-nerve condition called NAION, but the evidence does not show that users are broadly “going blind.” Here is what the studies and regulators actually found.
Read article
Does GLP-1 Exposure in Early Pregnancy Increase Birth-Defect Risk?
New human studies have not found a consistent, statistically significant increase in major congenital malformations after early GLP-1 exposure. The findings are reassuring, but they do not prove semaglutide, tirzepatide, or other GLP-1-based drugs are safe during pregnancy.
Read article
Does Tirzepatide Pass Into Breast Milk? What the Human Studies Found
Two small human lactation studies found tirzepatide was usually undetectable or present only at very low levels in breast milk. The results measure milk transfer—not infant safety—and important evidence gaps remain.
Read article
Does Semaglutide Extend Lifespan? What the New Mouse Study Actually Shows
A Nature study found longer median lifespan in older female mice treated with semaglutide. The result is notable—but it does not show that semaglutide extends human life.
Read article
Is BPC-157 in Human Clinical Trials? What NCT07803250 Actually Shows
A newly registered Phase 1 study plans to investigate BPC-157 following rotator-cuff repair. Here is what the record says, what conflicts, and what remains unknown.
Read article
What Did FDA Approve About Mimrylo (Rusfertide)?
FDA approved Mimrylo, the branded rusfertide medicine, after the phase 3 VERIFY trial. The approval is important—but product-specific.
Read article
Is Ipamorelin Banned in Sport? What the 2026 WADA List Says
WADA's 2026 Prohibited List expressly names ipamorelin under class S2 and prohibits it in and out of competition. Here is what that rule—and a recent provisional cycling suspension—actually means.
Read article
Did Avexitide Reduce Hypoglycemic Events by 55%? What the Phase 3 LUCIDITY Results Actually Show
A review of sponsor-reported Phase 3 LUCIDITY findings, the 55% relative event-rate reduction, safety reporting, and evidence limits.
Read articleRESEARCH RESOURCE PATHWAY
Compound research evidence library
Browse research-only literature overviews organized by exact compound name. Each page separates reported findings from analytical identity and evidence limitations.
BPC-157 research evidence
A source-conscious overview of preclinical evidence and study limitations.
GHK-Cu research evidence
Research context for GHK-Cu, terminology, methods, and study limitations.
KPV research evidence
Research context, sequence identity, documentation, and evidence limitations.
MOTS-C research evidence
Research context for a mitochondrial-derived peptide and its documentation needs.
PT-141 research evidence
A research-only review of nomenclature, identity, literature, and limitations.
Selank research evidence
Research context, peptide identity, sourcing records, and evidence limits.
TB-500 research evidence
Clarify nomenclature, sequence claims, laboratory identity, and source limitations.
Tesamorelin research evidence
Research context, identity documentation, analytical methods, and evidence limits.
RESEARCH RESOURCE PATHWAY
Research and editorial standards
See how sources, corrections, and document revisions are handled.
Scientific sourcing and editorial standards
How JD BioWorks selects sources, distinguishes evidence levels, and updates research content.
Corrections and document revision policy
How factual corrections, material updates, and superseded records are handled.
START WITH THE RESEARCH QUESTION